Aramex International LLC
News Detail
Press release News vom 23.08.2016
Aramex Announces Strategic Logistics Partnership with NewBridge Pharmaceuticals
Dubai, UAE; August 23, 2016: Aramex, a leading global provider of comprehensive logistics and transportation solutions, has recently announced its partnership with NewBridge Pharmaceuticals. As part of this collaboration, Aramex is now providing a range of logistics services for NewBridge in the Middle East, Africa, Canada and the UK. Based in Dubai, UAE, NewBridge pharmaceuticals is a regional specialty company providing a one-stop-solution to pharmaceuticals, biological, genomics and other innovative healthcare companies. The focus is on in-licensing and commercializing FDA and EMA/European approved innovative therapeutics and diagnostics that address unmet medical needs of diseases with high prevalence within the emerging markets of the Middle East & Africa region. Through the partnership, Aramex is managing the logistics of patient samples across any clinics and hospitals from the Middle East to the U.S. for advanced clinical testing. Aramex is also providing temperature controlled storage and transportation of medication for NewBridge from various distribution hubs in the UK and Canada to healthcare facilities within the Middle East and Africa. Furthermore, Aramex is providing NewBridge with customs clearance, secondary packaging, labeling, vaulting and guarded transport services as part of the partnership. Commenting on the agreement, Hussein Hachem, CEO of Aramex, said: “We are excited to have partnered with NewBridge Pharmaceuticals. This collaboration is a testimony to our healthcare solutions which not only enable our healthcare customers to grow globally, but also provide access to quality healthcare service to citizens across our region. By working closely with NewBridge we are able to further penetrate the healthcare market, take advantage of the increased demand for logistics services in the pharmaceutical industry and better support people who require medicine and other pharmaceutical needs to be delivered to them effectively and efficiently. Not only are we proud to be a part of improving peoples’ health in the region, but this partnership with NewBridge also attests to the quality and reliability of the logistics services that we provide.” Further commenting on the agreement, Joe Henein , CEO of NewBridge Pharmaceuticals, said: “This partnership with Aramex gives us significant opportunities to expand our business proposition and take advantage of the increasing demand for our solutions across the Middle East and Africa. We are dedicated to addressing the medical needs of our customers and this partnership allows us to reach more businesses and patients who rely on our full range of pharmaceutical services. Aramex also has a well-recognised brand, stable business and a leadership position in the region, making them an ideal partner for us to extend our reach in the market. The credibility and quality of their services makes them the best-suited business partner for the services we provide. We remain committed to servicing the Middle East and Africa and this partnership will allow us to serve more businesses and consumers who need critical medical attention in the region.” As the global healthcare market continues to develop, regulation and compliance for the transportation and storage of medicine is becoming more stringent. This collaboration between Aramex and NewBridge is consequently filling a gap in the market by ensuring medicines, human specimens and other pharmaceutical goods are being securely, safely and efficiently transported throughout the region in line with local regulations. In addition to having facility hubs based in the UK and Canada, Aramex plans to set up a third facility hub in the U.S. soon, and will continue to handle the storage, transport and delivery of NewBridge’s medicine and other pharmaceutical goods. - End -
About Aramex: Aramex (DFM: ARMX) is a leading global provider of comprehensive logistics and transportation solutions. Established in 1982 as an express operator, the company rapidly evolved into a global brand recognized for its customized services and innovative multi-product offering. Traded on the NASDAQ from 1997 to 2002, Aramex today is a publicly traded company on the Dubai Financial Market, employing more than 13,800 people in over 350 locations across 60 countries and leads a strong alliance network providing global presence, and bringing together 40 independent express companies from around the world. The range of services offered by Aramex includes integrated logistics solutions, international and domestic express delivery, freight forwarding, secure records and information management solutions, and e-services, including e-business solutions and Shop and Ship. For more information, please visit us at www.aramex.com. Please follow us on: About NewBridge Pharmaceuticals: NewBridge Pharmaceuticals is a regional specialty company providing a one-stop-solution to pharmaceuticals, biological, genomics and other innovative healthcare companies. The focus is on in-licensing and commercializing FDA and EMA/European approved innovative therapeutics and diagnostics that address unmet medical needs of diseases with high prevalence within the emerging markets of the Middle East & Africa region. NewBridge strives to successfully license and provide access to innovative medicines and improve health and quality of life of patients across the region. Current focus is mainly in the areas of Oncology, Immunology, NeuroScience, Gastro-Intestinal and Medical Nutrition. Future expansion includes manufacturing and the establishment of NewBridge propriety brands. NewBridge’s innovative business model and efficient commercialization capabilities is driven by successful and respected industry leaders with strong local and international track records. In addition, NewBridge has built internal functional capabilities in areas of Business Development, Regulatory Affairs, Medical Affairs, Pharmacovigilance and Commercial Sales and Marketing. NewBridge is financially backed by Burrill Life Sciences Capital Fund III, Kuwait Life Sciences Company (KLSC), the life science arm of National Technology Enterprises Company (NTEC), a Kuwait investment authority mandated fund, and Élan Science One Ltd, a company within the Perrigo group of companies. For more information: http://www.nbpharma.com For more PR information, please contact: Aramex International LLC Weber Shandwick |
